UNION therapeutics to present at the Dermatology Summit 2025, opening the week of the 43rd Annual J.P. Morgan Health Care Conference
Hellerup, Denmark, January 10, 2025 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that CEO Dr. Kim Kjøller will present at the Dermatology Summit, January 12th 2025 at the Hyatt Regency San Francisco.
Dr. Kjøller will be presenting at 3.15 pm (PST), Sunday January 12, 2025, and will provide an update on orismilast and its potential across immunology as a safe oral treatment amidst injectable biologics. The presentation will include recent data from Phase 2 studies of orismilast in atopic dermatitis as well as hidradenitis suppurativa, demonstrating good effect on lesions as well as early relief of core symptoms for patients. Orismilast has also generated positive results in psoriasis and is currently in development for ulcerative colitis, underscoring its potential as a safe oral treatment option across a broad range of immunological indications.
The UNION team will also participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, at the Westin St. Francis in San Francisco, CA.
Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com
About UNION therapeutics
UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com
About orismilast
Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases. Orismilast is developed to have more potent anti-inflammatory properties than previously marketed PDE4 inhibitors, enabled by higher selectivity for subtypes PDE4B and D.